FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667725> ?p ?o ?g. }

• W4385667725 endingPage "e8414502" @default.
• W4385667725 startingPage "e8414502" @default.
• W4385667725 abstract "Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Dimethyl fumarate (DMF) has been shown to induce apoptosis of lymphocytes, and thus used for treating relapsing-remitting multiple sclerosis and psoriasis. It is of interest that this drug also has a potent anti-tumor activity against a range of cancer cells. To date, glycolytic Inhibition and accumulation of oxidative stress through glutathione (GSH) oxidation have been proposed as potential mechanisms, but less data is available about leukemia cells. The Keap1-Nrf2 pathway is a major elimination system of reactive oxygen species (ROS) other than GSH-glutathione disulfide (GSSG) redox balance. Intracellular ROS induces nuclear translocation of Nrf2, which can subsequently bind to antioxidant response elements (ARE), and in turn promotes the expression of antioxidant genes. Previous studies indicate that Nrf2 inhibition can downregulate antioxidant gene levels, thereby leading to oxidative stress-derived apoptosis of cancer cells. Interestingly, a novel Bcl-2 inhibitor venetoclax (VEN) appeared to inhibit the Keap1-Nrf2 pathway by dissociating BCL-2/Nrf-2 interaction and promoting Nrf2 ubiquitination. This led us to hypothesize that DMF and VEN may have a synergistic anti-tumor effect against leukemia cells by dual inhibition of cellular redox systems. Aims: The first aim of this study is to examine the anti-leukemic effect of DMF in terms of oxidative stress and cellular metabolism. The second aim is to investigate the synergistic effect of DMF in combination with VEN against leukemia cells. Methods: Human acute myeloid leukemia cell lines (MOLM-14 and U937) were used to investigate the anti-leukemia effects of DMF in combination with VEN. Intracellular GSH and GSSG levels were quantified by luminescence-based assay. ROS accumulation and apoptosis rate were measured by flow cytometry. Nuclear translocation of Nrf2 in leukemia cells was determined by Western blotting. Quantitative real-time PCR was used to determine the expression levels of antioxidant genes. The extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured by Seahorse XFe96 analyzer. Results: Consistent with previous studies on cancer cells, DMF decreased the GSH/GSSG ratio in both MOLM-14 and U-937 cells. The ROS accumulation and cellular apoptosis rate were significantly increased by DMF treatment in a time- and dose-dependent manner. After N-acetylcysteine (NAC) treatment, GSH/GSSG ratio, ROS levels, and cell viabilities were all reverted to the basal level. The Western blotting revealed that DMF promotes nuclear translocation of Nrf2, suggesting a compensatory response to excess oxidative stress in leukemia cells. In fact, the mRNA expression levels of HO-1 and NQO-1 were upregulated, whereas they were almost completely restored by NAC or specific Nrf2 inhibitor ML385. DMF increased the ECAR in a dose-dependent manner, but decreased the coupled OCR levels, suggesting metabolic reprogramming to attenuate mitochondrial ROS generation. As has been shown in cancer cells, VEN hampered nuclear translocation of Nrf2 in leukemia cells to the same extent of ML385. VEN did not affect ROS levels when used as single agents, but significantly enhanced DMF-mediated oxidative stress. Furthermore, this combination induced more apoptosis of leukemia cells than did single agents. Summary/Conclusion: Our data demonstrate that DMF in combination with VEN can promote significant apoptosis of leukemia cells by inhibiting GSH activity and Nrf2-dependent anti-oxidant response. DMF/VEN may have the potential to become a novel therapeutic alternative to conventional VEN-based regimens.Keywords: Reactive oxygen species, Venetoclax, Acute myeloid leukemia, Antioxidants" @default.
• W4385667725 created "2023-08-09" @default.
• W4385667725 creator A5001663062 @default.
• W4385667725 creator A5005569246 @default.
• W4385667725 creator A5009975594 @default.
• W4385667725 creator A5024135264 @default.
• W4385667725 creator A5033038556 @default.
• W4385667725 creator A5035022237 @default.
• W4385667725 creator A5064956018 @default.
• W4385667725 creator A5074925412 @default.
• W4385667725 creator A5080292517 @default.
• W4385667725 creator A5081128913 @default.
• W4385667725 creator A5089194366 @default.
• W4385667725 date "2023-08-01" @default.
• W4385667725 modified "2023-09-27" @default.
• W4385667725 title "PB1757: NOVEL THERAPEUTIC STRATEGY TARGETING CELLULAR REDOX SYSTEMS USING DIMETHYL FUMARATE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA" @default.
• W4385667725 doi "https://doi.org/10.1097/01.hs9.0000973888.84145.02" @default.
• W4385667725 hasPublicationYear "2023" @default.
• W4385667725 type Work @default.
• W4385667725 citedByCount "0" @default.
• W4385667725 crossrefType "journal-article" @default.
• W4385667725 hasAuthorship W4385667725A5001663062 @default.
• W4385667725 hasAuthorship W4385667725A5005569246 @default.
• W4385667725 hasAuthorship W4385667725A5009975594 @default.
• W4385667725 hasAuthorship W4385667725A5024135264 @default.
• W4385667725 hasAuthorship W4385667725A5033038556 @default.
• W4385667725 hasAuthorship W4385667725A5035022237 @default.
• W4385667725 hasAuthorship W4385667725A5064956018 @default.
• W4385667725 hasAuthorship W4385667725A5074925412 @default.
• W4385667725 hasAuthorship W4385667725A5080292517 @default.
• W4385667725 hasAuthorship W4385667725A5081128913 @default.
• W4385667725 hasAuthorship W4385667725A5089194366 @default.
• W4385667725 hasBestOaLocation W43856677251 @default.
• W4385667725 hasConcept C104317684 @default.
• W4385667725 hasConcept C121608353 @default.
• W4385667725 hasConcept C181199279 @default.
• W4385667725 hasConcept C185592680 @default.
• W4385667725 hasConcept C203014093 @default.
• W4385667725 hasConcept C2776151105 @default.
• W4385667725 hasConcept C2776529522 @default.
• W4385667725 hasConcept C2776819417 @default.
• W4385667725 hasConcept C2777938653 @default.
• W4385667725 hasConcept C2778461978 @default.
• W4385667725 hasConcept C2778729363 @default.
• W4385667725 hasConcept C2779675984 @default.
• W4385667725 hasConcept C2780640218 @default.
• W4385667725 hasConcept C48349386 @default.
• W4385667725 hasConcept C502942594 @default.
• W4385667725 hasConcept C538909803 @default.
• W4385667725 hasConcept C54355233 @default.
• W4385667725 hasConcept C55493867 @default.
• W4385667725 hasConcept C86339819 @default.
• W4385667725 hasConcept C86803240 @default.
• W4385667725 hasConcept C96232424 @default.
• W4385667725 hasConcept C98274493 @default.
• W4385667725 hasConceptScore W4385667725C104317684 @default.
• W4385667725 hasConceptScore W4385667725C121608353 @default.
• W4385667725 hasConceptScore W4385667725C181199279 @default.
• W4385667725 hasConceptScore W4385667725C185592680 @default.
• W4385667725 hasConceptScore W4385667725C203014093 @default.
• W4385667725 hasConceptScore W4385667725C2776151105 @default.
• W4385667725 hasConceptScore W4385667725C2776529522 @default.
• W4385667725 hasConceptScore W4385667725C2776819417 @default.
• W4385667725 hasConceptScore W4385667725C2777938653 @default.
• W4385667725 hasConceptScore W4385667725C2778461978 @default.
• W4385667725 hasConceptScore W4385667725C2778729363 @default.
• W4385667725 hasConceptScore W4385667725C2779675984 @default.
• W4385667725 hasConceptScore W4385667725C2780640218 @default.
• W4385667725 hasConceptScore W4385667725C48349386 @default.
• W4385667725 hasConceptScore W4385667725C502942594 @default.
• W4385667725 hasConceptScore W4385667725C538909803 @default.
• W4385667725 hasConceptScore W4385667725C54355233 @default.
• W4385667725 hasConceptScore W4385667725C55493867 @default.
• W4385667725 hasConceptScore W4385667725C86339819 @default.
• W4385667725 hasConceptScore W4385667725C86803240 @default.
• W4385667725 hasConceptScore W4385667725C96232424 @default.
• W4385667725 hasConceptScore W4385667725C98274493 @default.
• W4385667725 hasIssue "S3" @default.
• W4385667725 hasLocation W43856677251 @default.
• W4385667725 hasLocation W43856677252 @default.
• W4385667725 hasOpenAccess W4385667725 @default.
• W4385667725 hasPrimaryLocation W43856677251 @default.
• W4385667725 hasRelatedWork W1993194916 @default.
• W4385667725 hasRelatedWork W2008817720 @default.
• W4385667725 hasRelatedWork W2052122421 @default.
• W4385667725 hasRelatedWork W2163338807 @default.
• W4385667725 hasRelatedWork W2377341619 @default.
• W4385667725 hasRelatedWork W2765590223 @default.
• W4385667725 hasRelatedWork W3030551982 @default.
• W4385667725 hasRelatedWork W3183236411 @default.
• W4385667725 hasRelatedWork W4226192588 @default.
• W4385667725 hasRelatedWork W4320507822 @default.
• W4385667725 hasVolume "7" @default.
• W4385667725 isParatext "false" @default.
• W4385667725 isRetracted "false" @default.
• W4385667725 workType "article" @default.